Patents by Inventor Origene Nyanguile

Origene Nyanguile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion respiratory syncytial virus inhibitors and use thereof
    Patent number: 11299518
    Abstract: The present invention relates novel peptides useful for the prevention and/or treatment of respiratory syncytial virus (RSV) infections.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 12, 2022
    Assignee: FONDATION THE ARK
    Inventors: Origene Nyanguile, Jean-Manuel Segura, Dominique Garcin
  • Respiratory syncytial virus (RSV) replication inhibitors
    Patent number: 10774114
    Abstract: The invention provides polypeptides interacting with the binding of the RSV phosphoprotein P with the RSV nucleoprotein N and methods of using such polypeptides in the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 15, 2020
    Assignee: FONDATION THE ARK
    Inventors: Origéne Nyanguile, Jean-François Eleouet, Marie Galloux
  • FUSION RESPIRATORY SYNCYTIAL VIRUS INHIBITORS AND USE THEREOF
    Publication number: 20190055291
    Abstract: The present invention relates novel peptides useful for the prevention and/or treatment of respiratory syncytial virus (RSV) infections.
    Type: Application
    Filed: March 2, 2017
    Publication date: February 21, 2019
    Inventors: ORIGENE NYANGUILE, JEAN-MANUEL SEGURA, DOMINIQUE GARCIN
  • RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS
    Publication number: 20170152292
    Abstract: The invention provides polypeptides interacting with the binding of the RSV phosphoprotein P with the RSV nucleoprotein N and methods of using such polypeptides in the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: March 10, 2015
    Publication date: June 1, 2017
    Inventors: ORIGÈNE NYANGUILE, JEAN-FRANÇOIS ELEOUET, MARIE GALLOUX
  • Macrocyclic indoles as hepatitis C virus inhibitors
    Patent number: 9334282
    Abstract: The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R1; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: May 10, 2016
    Assignee: Janssen Sciences Ireland UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Lili Hu, Sandrine Marie Helene Vendeville, Origéne Nyanguile, Abdellah Tahri
  • Macrocyclic Indoles as Hepatitis C Virus Inhibitors
    Publication number: 20130267511
    Abstract: The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R1; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 10, 2013
    Inventors: Pierre Jean-Marie Bernard Raboisson, Lili Hu, Sandrine Vendeville, Origene Nyanguile
  • Macrocyclic indoles as hepatitis C virus inhibitors
    Patent number: 8524716
    Abstract: The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R1; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 3, 2013
    Assignee: Janssen R&D Ireland
    Inventors: Pierre Jean-Marie Bernard Raboisson, Lili Hu, Sandrine Marie Helene Vendeville, Origène Nyanguile, Abdellah Tahri
  • BENZODIAZEPINES AS HCV INHIBITORS
    Publication number: 20090221559
    Abstract: The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to benzodiazepine compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: September 1, 2006
    Publication date: September 3, 2009
    Inventors: Jean-Francois Bonfanti, Frederic Marc Maurice Doublet, Origene Nyanguile, Pierre Jean-Marie Bernard Raboisson, Anne-Sophie Helene Marie Rebstock, Carlo Willy Maurice Boutton
  • Use of receptor sequences for immobilizing gene vectors on surfaces
    Publication number: 20070092489
    Abstract: The present invention relates to compositions and methods of immobilizing a viral vector to an implantable medical device, for example a vascular stent. Specifically, a composition for delivery of a therapeutic agent is provided which includes: a gene transfer vector, a surface and a modified protein, wherein the gene transfer vector is bound to the modified protein and the modified protein is covalently bound to the surface and wherein the composition is adapted to deliver the gene transfer vector to a mammalian cell. The viral vector is preferably an adenoviral vector and the modified protein is preferably CAR D1.
    Type: Application
    Filed: August 13, 2004
    Publication date: April 26, 2007
    Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Ilia Fishbein, Ivan Alferiev, Robert Levy, Origene Nyanguile
  • Synthetic transcriptional modulators and uses thereof
    Publication number: 20020004195
    Abstract: Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.
    Type: Application
    Filed: December 29, 2000
    Publication date: January 10, 2002
    Applicant: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Origene Nyanguile
  • Synthetic transcriptional modulators and uses thereof
    Patent number: 6183965
    Abstract: Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: February 6, 2001
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Origene Nyanguile
  • Synthetic transcriptional modulators and uses thereof
    Patent number: 6153383
    Abstract: Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: November 28, 2000
    Inventors: Gregory L. Verdine, Origene Nyanguile